References
- Kuaban C, Noeske J, Rieder HL, Aït-Khaled N, Abena Foe J, Trébucq A. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. Int J Tuberc Lung Dis. 2015;19(5):517–524. doi:10.5588/ijtld.14.0535
- Heysell SK, Ahmed S, Rahman MT, et al.. Hearing loss with kanamycin treatment for multidrug-resistant tuberculosis in Bangladesh. Eur Respir J. 2018;51(3):1701778.
- Isabel JGA, Miroslava FP, Rafael LL. Second-line injectable drugs for the treatment of multidrug-resistant tuberculosis. Why do we keep using them? Available from: http://www.ramr.org/articulos/volumen_19_numero_3/articulos_originales/articulos_originales_second_line_injectable_drugs_for_the_treatment_of_multidrug-resistant_tuberculosis_why_do_we_keep_using_them.pdf. Accessed November 22, 2021.
- Sagwa EL, Ruswa N, Mavhunga F, Rennie T, Leufkens HG, Mantel-Teeuwisse AK. Comparing amikacin and kanamycin-induced hearing loss in multidrug-resistant tuberculosis treatment under programmatic conditions in a Namibian retrospective cohort. BMC Pharmacol Toxicol. 2015;16(1). doi:10.1186/s40360-015-0036-7
- Dillard LK, Martinez RX, Perez LL, Fullerton AM, Chadha S, McMahon CM. Prevalence of aminoglycoside-induced hearing loss in drug-resistant tuberculosis patients: a systematic review: ototoxic hearing loss in drug-resistant tuberculosis. J Infect. 2021;83:27–36.
- World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. World Health Organization; 2019.
- Baqar T, Ahmad S, Rai S. Ototoxicity in MDR-TB patients on category-4 regimen: a case report. Era’s J Med Res. 2020;7(2):257–259. doi:10.24041/ejmr2020.45